BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24660850)

  • 1. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
    Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
    Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
    Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
    Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe hypocalcemia due to lenalidomide.
    Kong S; Collet P; Marotte H; Thomas T
    Joint Bone Spine; 2015 Oct; 82(5):380-1. PubMed ID: 25726251
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
    García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
    Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
    Barley K; He W; Agarwal S; Jagannath S; Chari A
    Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 9. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
    Monaghan SA; Dai L; Mapara MY; Normolle DP; Gollin SM; Lentzsch S
    Leuk Lymphoma; 2013 Sep; 54(9):1965-74. PubMed ID: 23216269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
    Vallet S; Palumbo A; Raje N; Boccadoro M; Anderson KC
    Leuk Lymphoma; 2008 Jul; 49(7):1238-45. PubMed ID: 18452080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
    Cabrera César E; Fernández Aguirre MC; González Fernández A
    Arch Bronconeumol; 2017 Jun; 53(6):355-356. PubMed ID: 27939513
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Wiernik PH
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
    Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
    Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
    João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
    Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
    Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
    Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
    Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
    Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
    Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
    Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide--the phoenix rises.
    List AF
    N Engl J Med; 2007 Nov; 357(21):2183-6. PubMed ID: 18032768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.